← BrightSpring Health Services, Inc. Common Stock overview

BrightSpring Health Services, Inc. Common Stock vs Adapthealth: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

August 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Latest
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Adapthealth Corp (AHCO)

Q3 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

August 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

Latest
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.